Indo US Bio-Tech Ltd. (IN:INDOUS)
:INDOUS
Want to see IN:INDOUS full AI Analyst Report?
INDOUS Stock Chart & Stats
₹108.00
-₹4.85(-1.77%)
At close: 4:00 PM EST
₹108.00
-₹4.85(-1.77%)
Day’s Range― - ―
52-Week Range₹87.10 - ₹205.10
Previous CloseN/A
Volume1.20K
Average Volume (3M)983.00
Market Cap
₹1.78B
Enterprise Value₹2.27B
Total Cash (Recent Filing)₹5.88M
Total Debt (Recent Filing)₹276.43M
Price to Earnings (P/E)13.7
Beta0.94
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.56
Shares Outstanding20,052,000
10 Day Avg. Volume961
30 Day Avg. Volume983
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.24
Price to Sales (P/S)1.87
P/FCF Ratio-13.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthA 71.94% YoY revenue jump in FY2026 signals durable market traction for the company’s seeds and commercialization model. Sustained top-line growth supports scale in production, distribution and R&D, enabling long-term competitive positioning if margins are preserved.
Improved CapitalizationEquity and asset expansion strengthen the balance sheet, providing a buffer for seasonal agricultural cycles and funding multi-year seed multiplication. A larger equity base improves resilience to shocks and supports longer-term investments in product development and distribution.
Focused Seed Agribusiness ModelA vertically integrated seed business—R&D, multiplication, processing and marketing—creates durable advantages: proprietary genetics, quality control and distribution relationships. These structural capabilities support repeatable revenue and product differentiation over time.
Bears Say
Negative Operating & Free Cash FlowSustained negative operating (~-126M) and free cash flow (~-150M) impair liquidity and force reliance on external funding. Over a multi-month horizon this can limit capacity to finance seed production cycles, dealer support and R&D, raising execution and growth risks.
Rising Total DebtTotal debt rising to ~370M from prior modest leverage increases refinancing and interest burden risk. Coupled with weak cash conversion, higher debt reduces financial flexibility to fund seasonal working capital or capex and elevates solvency risk in adverse seasons.
Earnings Quality And Margin PressureNet income falling despite strong revenue growth and previously thin operating margins suggests cost inflation, adverse mix or one-offs that erode durable profitability. Weak margin structure limits ability to self-fund growth and absorb commodity or input cost shocks.
Indo US Bio-Tech Ltd. News
INDOUS FAQ
What was Indo US Bio-Tech Ltd.’s price range in the past 12 months?
Indo US Bio-Tech Ltd. lowest stock price was ₹87.10 and its highest was ₹205.10 in the past 12 months.
What is Indo US Bio-Tech Ltd.’s market cap?
Indo US Bio-Tech Ltd.’s market cap is ₹1.78B.
When is Indo US Bio-Tech Ltd.’s upcoming earnings report date?
Indo US Bio-Tech Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 54 days.
How were Indo US Bio-Tech Ltd.’s earnings last quarter?
Indo US Bio-Tech Ltd. released its earnings results on May 30, 2026. The company reported ₹0.98 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.98.
Is Indo US Bio-Tech Ltd. overvalued?
According to Wall Street analysts Indo US Bio-Tech Ltd.’s price is currently Overvalued.
Does Indo US Bio-Tech Ltd. pay dividends?
Indo US Bio-Tech Ltd. pays a N/A dividend of ₹0.25 which represents an annual dividend yield of N/A. See more information on Indo US Bio-Tech Ltd. dividends here
What is Indo US Bio-Tech Ltd.’s EPS estimate?
Indo US Bio-Tech Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Indo US Bio-Tech Ltd. have?
Indo US Bio-Tech Ltd. has 20,052,000 shares outstanding.
What happened to Indo US Bio-Tech Ltd.’s price movement after its last earnings report?
Indo US Bio-Tech Ltd. reported an EPS of ₹0.98 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 4.522%.
Which hedge fund is a major shareholder of Indo US Bio-Tech Ltd.?
Currently, no hedge funds are holding shares in IN:INDOUS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Indo US Bio-Tech Ltd.
Indo Us Bio-Tech Ltd. is an Indian firm specializing in the entire seed value chain, encompassing production, processing, packaging, and distribution across India. Their diverse product lineup features an extensive selection of vegetable seeds, including tomato, okra, bottle gourd, brinjal, carrot, cluster bean, bitter gourd, ridge gourd, cucumber, cabbage, radish, sponge gourd, various peppers (chili and sweet pepper), beetroot, cowpea, coriander, onion, watermelon, and muskmelon. The company also provides ornamental flower seeds, cotton seeds, and a variety of oilseeds such as castor, groundnut, sesame, mustard, and soybean. Furthermore, their offerings extend to spice seeds like cumin and psyllium (isabgul), pulse seeds including val, gram, black gram, and green gram, and cereal seeds such as wheat, maize, bajra, and pigeon pea. Beyond its domestic operations, Indo Us Bio-Tech Ltd. actively exports its agricultural products. The company was founded in 2004 and is headquartered in Ahmedabad, India.
Technical Analysis
Astec Lifesciences Limited
―
Best Agrolife Ltd.
―
India Pesticides Ltd.
―
Nath Bio-Genes (India) Ltd.
―
Indogulf Cropsciences Limited
―